Mary Daniel
Family · Centerton, ARNPI 1073836466
Payments from drug & device makers
Across 306 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$614
- Lilly USA, LLC$549
- Novo Nordisk$469
- GSK$415
- Pfizer$391
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,263100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,126 |
| AstraZeneca | 30 | $614 |
| Lilly USA, LLC | 36 | $549 |
| Novo Nordisk | 26 | $469 |
| GSK | 30 | $415 |
| Pfizer | 24 | $391 |
| Amgen(2 entities) | 17 | $283 |
| Bayer | 9 | $175 |
| Boehringer Ingelheim | 9 | $151 |
| Merck | 7 | $119 |
| Dynavax Technologies Corporation | 5 | $101 |
| Supernus Pharmaceuticals, Inc. | 5 | $84 |
| Phathom Pharmaceuticals, Inc. | 5 | $81 |
| Abbott | 4 | $68 |
| Astellas Pharma US Inc | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Dexcom, Inc. | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Exact Sciences | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Biogen | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Johnson & Johnson | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $7 |
How this compares
$5,263 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 37 | $61,835 |
| JardianceEmpagliflozin | 23 | $33,185 |
| OzempicSemaglutide | 18 | $28,130 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $25,589 |
| MyrbetriqMirabegron | 15 | $17,286 |
| LinzessLinaclotide | 15 | $8,026 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,136 |
| Pregabalin | 41 | $2,468 |
| Celecoxib | 50 | $1,291 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,113 |
| Atorvastatin Calcium | 131 | $979 |
| Metoprolol Succinate | 56 | $754 |
| Gabapentin | 58 | $671 |
| SynthroidLevothyroxine Sodium | 13 | $659 |
| Duloxetine Hcl | 36 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $549 | $61,83537 claims |
| Boehringer IngelheimJardiance | $151 | $33,18523 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $415 | $30,72553 claims |
| Novo NordiskOzempic | $469 | $28,13018 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $17,28615 claims |
| AbbVieLinzess, Synthroid | $1,126 | $8,68528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Centerton
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.